|
Market Closed -
OTC Markets
13:20:47 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -99.00% |
| Market Cap | 6.24M 4.44M 3.99M 3.68M 3.34M 422M 6.31M 44.13M 17.53M 221M 16.67M 16.31M 701M | P/E 2022 |
-2.09x | P/E 2023 | -0.45x |
|---|---|---|---|---|---|
| Enterprise Value | 64.5M 45.92M 41.21M 38.05M 34.51M 4.36B 65.29M 456M 181M 2.29B 172M 169M 7.25B | EV / Sales 2022 |
3.37x | EV / Sales 2023 | 1.35x |
| Free-Float |
52.66% | Yield 2022 * |
-
| Yield 2023 | - |
| Current year | 0 |  | 0 |
| 1 year | 0 | | 0 |
| 3 years | 0 | | 0.25 |
| 5 years | 0 | | 0.68 |
| 10 years | 0 | | 1.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
CEO | Chief Executive Officer | 67 | 2003-03-26 |
Pascal Tougas
DFI | Director of Finance/CFO | - | 2023-11-19 |
Frédéric Dumais
IRC | Investor Relations Contact | - | 2019-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
CHM | Chairman | 67 | 2024-08-05 |
Richard MacKay
CHM | Chairman | 91 | 2018-07-24 |
Marc Léger
BRD | Director/Board Member | 67 | 2022-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% | ||
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% | ||
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 98 | |
| +0.22% | -0.14% | +55.12% | +128.82% | 1,140B | |
| +0.91% | +3.61% | +41.21% | +84.57% | 641B | |
| -0.12% | -0.93% | +25.59% | +106.14% | 507B | |
| +0.63% | +2.33% | +49.21% | +67.82% | 383B | |
| +0.86% | -4.37% | +61.16% | +37.93% | 347B | |
| +1.02% | +1.80% | +24.84% | +53.75% | 293B | |
| -0.25% | +1.62% | +2.20% | +26.65% | 266B | |
| +0.75% | +2.05% | +53.85% | +71.25% | 240B | |
| +0.25% | +1.64% | +32.05% | +107.62% | 197B | |
| Average | +0.43% | +1.04% | +38.36% | +76.06% | 401.38B | |
| Weighted average by Cap. | +0.44% | +0.96% | +42.20% | +88.48% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.74M 19.75M 17.73M 16.37M 14.84M 1.88B 28.09M 196M 77.95M 983M 74.15M 72.56M 3.12B | 53.91M 38.38M 34.45M 31.81M 28.84M 3.65B 54.57M 381M 151M 1.91B 144M 141M 6.06B |
| Net income | -25.75M -18.33M -16.45M -15.19M -13.78M -1.74B -26.06M -182M -72.33M -913M -68.81M -67.34M -2.89B | -27.81M -19.8M -17.77M -16.41M -14.88M -1.88B -28.15M -197M -78.12M -986M -74.32M -72.73M -3.13B |
| Net Debt | 38.94M 27.72M 24.88M 22.98M 20.83M 2.63B 39.42M 275M 109M 1.38B 104M 102M 4.38B | 58.26M 41.48M 37.23M 34.37M 31.17M 3.94B 58.97M 412M 164M 2.07B 156M 152M 6.55B |
Employees
70
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VPHIF Stock
Select your edition
All financial news and data tailored to specific country editions
